Multivariate analysis
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| aGVHD grade 2-4, d 100 | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.83 | 0.90-3.71 | .10 |
| Race/ethnicity | |||
| White, non-Hispanic | Reference | ||
| White, Hispanic | 0.48 | 0.19-1.23 | .13 |
| Black | 1.88 | 0.70-5.07 | .21 |
| Asian | 1.91 | 0.71-5.14 | .20 |
| aGVHD grade 3-4, d 100 | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 2.89 | 0.86-9.77 | .09 |
| Remission status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 1.49 | 0.46-4.78 | .51 |
| CR2 | NE | NE | NE |
| ≥CR3 | 7.71 | 1.24-47.78 | .03 |
| Race/ethnicity | |||
| White, non-Hispanic | Reference | ||
| White, Hispanic | 0.19 | 0.06-0.56 | .003 |
| Black | 0.36 | 0.03-4.05 | .41 |
| Asian | 0.46 | 0.07-3.02 | .42 |
| cGVHD, 2 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.91 | 1.28-2.85 | .002 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.56 | 1.01-2.41 | .04 |
| NRM, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 2.75 | 1.51-4.99 | .001 |
| Relapse, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 0.50 | 0.31-0.82 | .006 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 2.03 | 1.14-3.64 | .02 |
| CR2 | 2.73 | 1.38-5.38 | .004 |
| ≥CR3 | 3.87 | 1.40-10.68 | .009 |
| PFS, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.09 | 0.77-1.54 | .63 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.48 | 1.02-2.17 | .04 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 1.33 | 0.88-2.00 | .18 |
| CR2 | 2.349641 | 1.43-3.87 | .001 |
| ≥CR3 | 4.608024 | 2.04-10.43 | <.001 |
| OS, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.77 | 1.16-2.71 | .008 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.65 | 1.04-2.61 | .03 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 0.79 | 0.48-1.29 | .34 |
| CR2 | 1.91 | 1.11-3.31 | .02 |
| ≥CR3 | 3.55 | 1.37-9.20 | .009 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| aGVHD grade 2-4, d 100 | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.83 | 0.90-3.71 | .10 |
| Race/ethnicity | |||
| White, non-Hispanic | Reference | ||
| White, Hispanic | 0.48 | 0.19-1.23 | .13 |
| Black | 1.88 | 0.70-5.07 | .21 |
| Asian | 1.91 | 0.71-5.14 | .20 |
| aGVHD grade 3-4, d 100 | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 2.89 | 0.86-9.77 | .09 |
| Remission status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 1.49 | 0.46-4.78 | .51 |
| CR2 | NE | NE | NE |
| ≥CR3 | 7.71 | 1.24-47.78 | .03 |
| Race/ethnicity | |||
| White, non-Hispanic | Reference | ||
| White, Hispanic | 0.19 | 0.06-0.56 | .003 |
| Black | 0.36 | 0.03-4.05 | .41 |
| Asian | 0.46 | 0.07-3.02 | .42 |
| cGVHD, 2 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.91 | 1.28-2.85 | .002 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.56 | 1.01-2.41 | .04 |
| NRM, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 2.75 | 1.51-4.99 | .001 |
| Relapse, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 0.50 | 0.31-0.82 | .006 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 2.03 | 1.14-3.64 | .02 |
| CR2 | 2.73 | 1.38-5.38 | .004 |
| ≥CR3 | 3.87 | 1.40-10.68 | .009 |
| PFS, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.09 | 0.77-1.54 | .63 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.48 | 1.02-2.17 | .04 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 1.33 | 0.88-2.00 | .18 |
| CR2 | 2.349641 | 1.43-3.87 | .001 |
| ≥CR3 | 4.608024 | 2.04-10.43 | <.001 |
| OS, 4 y | |||
| Donor | |||
| Haploidentical <35 y | Reference | ||
| MUD ≥35 y | 1.77 | 1.16-2.71 | .008 |
| Patient age, y | |||
| <40 | Reference | ||
| ≥40 | 1.65 | 1.04-2.61 | .03 |
| Disease status | |||
| CR1-MRD–negative | Reference | ||
| CR1-MRD–positive | 0.79 | 0.48-1.29 | .34 |
| CR2 | 1.91 | 1.11-3.31 | .02 |
| ≥CR3 | 3.55 | 1.37-9.20 | .009 |
NE, nonevaluable.